PhRMA Appoints Senior VP of Federal Advocacy

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 03-03-2014 15:08


The Pharmaceutical Research and Manufacturers of America (PhRMA) announced the appointment of Charles “Chuck” Clapton to the position of senior vice-president, federal advocacy, effective March 17, 2014.

In this capacity, Clapton will be responsible for leading PhRMA’s federal government affairs initiatives and advancing its legislative agenda, working with a wide array of stakeholders to develop and advocate for health policies that foster innovation and ensure patient access to new medicines in the US and around the world. He will report to Chip Davis, executive vice-president, advocacy and member relations.

Most recently, Clapton worked as a partner at the international law firm HoganLovells, where he represented health care clients on legislative and regulatory matters. Prior to joining HoganLovells, Clapton worked for 17 years on Capitol Hill, where he held several leadership positions on the House Energy & Commerce Committee, Ways & Means Committee, Office of the Speaker and the Senate Health, Education, Labor and Pensions Committee.

During his time with the House and Senate, Clapton worked on reimbursement and coverage initiatives, including the Medicare Modernization Act that created the highly successful Medicare Part D drug program. In addition, he has extensive experience with policy issues related to FDA review and approval of new medicines, the distribution and use of non-FDA approved drugs, and other critical patient safety matters.

Source: PhRMA


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription